Aleniglipron and elecoglipron are investigational oral GLP-1 drugs that have reached phase 3 [2] [5]. If you are comparing GLP-1 pill and injection prices, distinguish approved products from drugs still in trials. A trial result cannot establish an approval date or retail price.
Aleniglipron
The ACCESS phase 2b trial randomized 230 adults with overweight or obesity [1]. At 36 weeks, the 45 mg, 90 mg and 120 mg groups lost an estimated 8.2, 9.8 and 11.3 percentage points more than placebo, respectively. In its November SEC filing, Structure Therapeutics said its phase 3 ACCOMPLISH program was underway [2].
Elecoglipron
Researchers studied blood glucose and weight in separate phase 2 programs. Our elecoglipron guide gives more context on its early results. SOLSTICE primarily measured hemoglobin A1C in adults with type 2 diabetes [3]. VISTA assessed weight outcomes in adults with overweight or obesity [4]. AstraZeneca is testing the drug for weight management in registered phase 3 studies [5].
TERN-601
Terns Pharmaceuticals stopped developing TERN-601 after liver enzyme elevations in three phase 2 participants [6]. One event was reported as serious drug-induced liver injury. The findings concern this candidate and do not establish the liver risk of other GLP-1 pills.
Which pills are already approved in the US?
Wegovy tablets contain semaglutide, and Foundayo tablets contain orforglipron [7] [8]. The FDA has approved both for weight management in eligible adults. Each has its own label and instructions.